Fundraising Fox
Venus Concept
Toronto, US · Founded 2009 · Delaware corporation · 421 employees on LinkedIn · 5 known investors
Find your way into Venus Concept
Sign up to see every warm intro you have to Venus Concept
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Venus Concept team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies. It serves medical spas, dermatologists, plastic surgeons, and hair transplant physicians across more than 60 countries.
Founders & leadership
Venus Concept was founded in 2009 by Domenic Serafino.
KG
Kirk GunhusChief Revenue Officer (CRO)2025–2026Kirk Gunhus held management positions at Ciba Vision and Medicis, where he sold aesthetic treatments including Restylane and Dysport, before joining Zeltiq as regional director. He is now Executive Officer at Venus Concept, which develops energy-based medical aesthetic devices for dermatology and cosmetic applications.
RP
Ross PortaroExecutive Vice-President Commercial StrategyRoss Portaro is an executive officer at Venus Concept, a medical device company developing non-invasive energy-based aesthetic devices. He has held senior leadership positions in the medical device and healthcare sectors, with experience in commercial strategy, global expansion, product portfolio management, and organizational restructuring.
MK
Melissa KangChief Product OfficerMelissa Kang is an Executive Officer at Venus Concept with over 20 years of experience in medical aesthetics, including roles in marketing, product management, R&D, regulatory affairs, and business development for toxins, dermal fillers, and medical devices. She holds an MBA from Queen's University, a CPA and CMA designation, and a BSc in Chemistry, and has led cross-functional global teams across more than 60 countries.
DD
Dominic Della PennaExecutive
RD
Rajiv De SilvaChief Executive Officer and Director
JM
James McCollumDirector, President and Chief Executive Officer
WK
William KelleyNamed on SEC filing
GV
Greg Van StaverenNamed on SEC filing
Investors · 5
APERTURE Venture Partnerslisted by APERTURE Venture PartnersNew York · $1M – $5M
How we know: APERTURE Venture Partners's portfolio page · Not right? Tell us
Essex Woodlands Healthcare Partnerslisted by Essex Woodlands Healthcare PartnersNew York · $20M – $80M
How we know: Essex Woodlands Healthcare Partners's portfolio page · Not right? Tell us
Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30Mvia Bakker · board
How we know: Longitude Capital's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · the VCSheet dataset · Not right? Tell us
HealthQuest CapitalreportedRedwood City
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$219.3M disclosed across 13 of 14 rounds · 2013–2026
▶$1.5MraisedApr 2026 · 2 investors · Other Health CareRule 506(b)
▶$1.5MraisedApr 2026 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kirk GunhusExecutive Officer
- Ross PortaroExecutive Officer
- Anna GeorgiadisExecutive Officer
- Melissa KangExecutive Officer
- Michael MandarelloExecutive Officer
- Avinash AminDirector
- Dominic Della PennaExecutive Officer
- Rajiv De SilvaExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedMar 2024 · 2 investors · Other Health CareRule 506(b)
▶$1.1MraisedMar 2024 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Hemanth VargheseExecutive Officer
- Anthony NataleDirector
- Keith SullivanDirector
- S. Tyler HollmigDirector
- Rajiv De SilvaExecutive Officer, Director
- Fritz LaPorteDirector
- Domenic Della PennaExecutive Officer
- Louise LacchinDirector
- Scott BarryDirector
- Garheng KongDirector
- Michael MandarelloExecutive Officer
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- Sales commissions
- $83.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMay 2023 · 2 investors · Other Health CareRule 506(b)
▶$2MraisedMay 2023 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Domenic Della PennaExecutive Officer
- Richard Scott BarryDirector
- Keith SullivanDirector
- Stanley Tyler HollmigDirector
- Hemanth VargheseExecutive Officer
- Louise LacchinDirector
- Anna GeorgiadisExecutive Officer
- William McGrailExecutive Officer
- Ross PortaroExecutive Officer
- Garheng KongDirector
- Fritz LaPorteDirector
- Michael MandarelloExecutive Officer
- Anthony NataleDirector
- Rajiv De SilvaExecutive Officer, Director
- Offering amount
- $9M
- Amount sold
- $2M
- Minimum investment
- $500K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedNov 2022 · 11 investors · Other Health CareRule 506(b)
▶$6.7MraisedNov 2022 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard Scott BarryDirector
- Keith SullivanDirector
- Michael MandarelloExecutive Officer
- Louise LacchinDirector
- Anna GeorgiadisExecutive Officer
- Yoni IgerExecutive Officer
- Fritz LaPorteDirector
- Garheng KongDirector
- William McGrailExecutive Officer
- Rajiv De SilvaDirector, Executive Officer
- Stanley Tyler HollmigDirector
- Ross PortaroExecutive Officer
- Domenic Della PennaExecutive Officer
- Soren Maor SinayExecutive Officer
- Anthony NataleDirector
- Anat KotlerExecutive Officer
- Hemanth VargheseExecutive Officer
- Offering amount
- $6.7M
- Amount sold
- $6.7M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedDec 2021 · 1 investors · OtherRule 506(b)
▶$4.7MraisedDec 2021 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Louise LacchinDirector
- Fritz LaPorteDirector
- Domenic SerafinoExecutive Officer, Director
- Keith SullivanDirector
- Anthony NataleDirector
- Garheng KongDirector
- Scott BarryExecutive Officer, Director
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$12.3MraisedDec 2021 · 9 investors · OtherRule 506(b)
▶$12.3MraisedDec 2021 · 9 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Louise LacchinDirector
- Scott BarryDirector
- Domenic SerafinoExecutive Officer, Director
- Fritz LaPorteDirector
- Garheng KongDirector
- Anthony NataleDirector
- Keith SullivanDirector
- Offering amount
- $12.3M
- Amount sold
- $12.3M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$50.5MraisedNov 2019 · 28 investors · Other Health CareRule 506(b)
▶$50.5MraisedNov 2019 · 28 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Scott BarryDirector
- Soeren Maor SinayExecutive Officer
- William KelleyExecutive Officer
- Melissa KangExecutive Officer
- Yoni IgerExecutive Officer
- Anna GeorgiadisExecutive Officer
- Domenic Di SistoExecutive Officer
- Domenic Della PennaExecutive Officer
- Frederic MollDirector
- Keith SullivanDirector
- Anthony NataleDirector
- Fritz LaPorteDirector
- Louise LacchinDirector
- Garheng KongDirector
- Boris VaynbergExecutive Officer
- Juliet Tammenoms BakkerDirector
- Domenic SerafinoExecutive Officer, Director
- Offering amount
- $50.5M
- Amount sold
- $50.5M
- Sales commissions
- $1.1M
- Placement agents
- Northland Securities, Inc., Oppenheimer & Co. Inc., Evercore Group L.L.C.
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.1MraisedAug 2019 · 9 investors · Other Health CareRule 506(b)
▶$14.1MraisedAug 2019 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Anna GeorgiadisExecutive Officer
- Domenic Della PennaExecutive Officer
- Domenic SerafinoExecutive Officer, Director
- Juliet BakkerDirector
- Garheng KongDirector
- Maor SinayExecutive Officer
- Louise LacchinDirector
- Fritz LaPorteDirector
- Anthony NataleDirector
- Boris VaynbergExecutive Officer
- Domenic Di SistoExecutive Officer
- Scott BarryDirector
- Yoni IgerExecutive Officer
- Melissa KangExecutive Officer
- William KelleyExecutive Officer
- Offering amount
- $14.1M
- Amount sold
- $14.1M
- First sale
- Aug 2019
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Venus Concept.
Frequently asked questions
- What does Venus Concept do?
- Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies. It serves medical spas, dermatologists, plastic surgeons, and hair transplant physicians across more than 60 countries.
- Who founded Venus Concept?
- Venus Concept was founded by Domenic Serafino in 2009.
- Who are Venus Concept's investors?
- Venus Concept's investors include APERTURE Venture Partners, Essex Woodlands Healthcare Partners, Longitude Capital, Clarus Ventures, HealthQuest Capital.
- How much funding has Venus Concept raised?
- Venus Concept has disclosed $219.3M raised across 13 of its 14 known rounds.
- Where is Venus Concept headquartered?
- Venus Concept is headquartered in Toronto, US.